The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Tysabri (natalizumab) Market During The Forecast Period?
The tysabri (natalizumab) market size has experienced significant expansion over recent years. It is projected to increase from $2.66 million in 2025 to $2.87 million in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. The historical growth of this market can be linked to several factors, including the rising prevalence of multiple sclerosis, the approval of natalizumab therapy, its adoption by neurologists, the existing unmet need in aggressive ms, and the expansion of infusion centers.
The market for tysabri (natalizumab) is projected to experience robust expansion in the coming years, anticipated to reach $3.87 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. This growth during the projection period stems from increased MS diagnosis rates, better infusion infrastructure, strengthened risk mitigation programs, an increase in specialty neurology services, and ongoing support for long-term clinical outcomes. Key trends identified for the forecast period encompass the expanding application of monoclonal antibodies in MS, a stronger inclination towards highly effective disease-modifying therapies, the broadening of outpatient infusion care options, enhanced safety and risk monitoring protocols, and an increasing emphasis on managing progressive MS.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19942&type=smp
What Key Drivers Are Fueling The Growth Of The Tysabri (natalizumab) Market?
The increasing prevalence of autoimmune disorders is projected to fuel the expansion of the tysabri (natalizumab) market moving forward. Autoimmune conditions involve the immune system erroneously attacking the body’s own cells, tissues, or organs, leading to inflammation and damage that manifest as chronic illnesses such as rheumatoid arthritis or multiple sclerosis, with their origins involving both genetic and environmental elements. The rise in these disorders stems from factors including genetic predisposition, environmental triggers, and improvements in awareness and diagnostic methods, resulting in a higher identification rate of cases. Tysabri proves beneficial for autoimmune disorders by targeting specific immune cells, thereby preventing inflammation and subsequent damage, which aids in treating conditions like multiple sclerosis and Crohn’s disease. As an illustration, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, in February 2024, it was reported that by 2025, approximately 562,378 Australians are expected to be living with rheumatoid arthritis (RA), representing 14% of the entire arthritis population. Thus, the growing incidence of autoimmune disorders is propelling growth within the tysabri (natalizumab) market.
How Is The Tysabri (natalizumab) Market Organized By Segment Classification?
The tysabri (natalizumab) market covered in this report is segmented –
1) By Clinical Indication: Multiple Sclerosis, Crohn’s Disease
2) By Patient Setting: Inpatient, Outpatient
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
What Market Trends Are Affecting The Tysabri (natalizumab) Market?
Key companies operating within the Tysabri (natalizumab) market are prioritizing the expansion of treatment options through alternative solutions, including biosimilars. This strategy aims to deliver more effective therapies to patients, thereby improving their quality of life and disease management. Biosimilars to Tysabri present an economical alternative for managing highly active relapsing-remitting multiple sclerosis, enhancing accessibility to crucial treatment, particularly in regions with limited resources. As an illustration, Sandoz Group AG, a pharmaceutical firm based in Switzerland, launched Tyruko (natalizumab) in January 2024. Tyruko is recognized as the inaugural and sole biosimilar to Tysabri, indicated for treating adults afflicted with highly active relapsing-remitting multiple sclerosis (RRMS). This launch reinforces Sandoz’s biosimilar portfolio and is intended to broaden access to effective and budget-friendly treatments for individuals living with multiple sclerosis.
Who Are The Industry Participants Involved In The Tysabri (natalizumab) Market?
Major companies operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics
Get The Full Tysabri (natalizumab) Market Report:
https://www.thebusinessresearchcompany.com/report/tysabri-natalizumab-global-market-report
Which Region Leads The Tysabri (natalizumab) Market In Overall Market Size?
North America was the largest region in the tysabri (natalizumab) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tysabri (natalizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Tysabri (natalizumab) Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/tysabri-natalizumab-global-market-report
Browse Through More Reports Similar to the Global Tysabri (natalizumab) Market 2026, By The Business Research Company
Bevacizumab Biosimilars Market Report 2026
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
Adalimumab Infliximab And Etanercept Biosimilars Market 2026
Tylosin Market Report 2026
https://www.thebusinessresearchcompany.com/report/tylosin-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model